Head-to-head · free
Genmab vs iRhythm Technologies, Inc.
GMAB vs IRTC — return on capital, cash generation, margins and balance sheet side by side.
GMAB
3 / 4
measures where GMAB leads
IRTC
1 / 4
measures where IRTC leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | GMAB | IRTC · FY2025 |
|---|---|---|
| Revenue | — | $747.1M |
| Net income | — | (44.6M) |
| Revenue growth (yearly, multi-year) | — | 23.3% |
| Free cash flow | — | $34.5M |
| Free cash flow margin | — | 4.6% |
| Net cash / (debt) | — | — |
| ROIC | 10.1% | — |
| Return on equity | 17.5% | -36.6% |
| Gross margin | 93.6% | 70.6% |
| Operating margin | 33.6% | -6.7% |
| Net debt / EBITDA | 3.13x | -13.37x |
Figures are as reported by each company; latest fiscal year shown.
Where iRhythm Technologies, Inc.'s cash went (FY2025)
- Capital spending
- $46.3M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free